ChanBio is a biopharmaceutical company dedicated to the development of functional antibody-based modulators active on ion channels and G-protein-coupled receptors (GPCRs). The company is developing treatments for multiple sclerosis as well as other autoimmune, cardiovascular, cancer-related, and pain disorders.
ChanBio operates out of the Merck Serono Israel, the Bioincubator of Merck Inc.
Cumulative Funding Raised Over Time ($)
Employees Over Time
ChanBio Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Jul 31, 2016
www.natureindex.com
ChanBio Ltd.
undefined
Nov 28, 2013
www.globes.co.il
Metabomed, ChanBio join Merck Serono Israel Bioincubator
#Partners
Nov 26, 2013
bciq.biocentury.com
For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and provides in-depth, integrated analysis and context on clinical, strategic, financial, regulatory and pol
Metabomed, ChanBio join Merck Serono Israel Bioincubator
#Partners
Nov 26, 2013
bciq.biocentury.com
For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and provides in-depth, integrated analysis and context on clinical, strategic, financial, regulatory and pol